SI9520080B - Substituirane pirimidinske spojine in njihova uporaba - Google Patents

Substituirane pirimidinske spojine in njihova uporaba Download PDF

Info

Publication number
SI9520080B
SI9520080B SI9520080A SI9520080A SI9520080B SI 9520080 B SI9520080 B SI 9520080B SI 9520080 A SI9520080 A SI 9520080A SI 9520080 A SI9520080 A SI 9520080A SI 9520080 B SI9520080 B SI 9520080B
Authority
SI
Slovenia
Prior art keywords
alkyl
stands
halogen
formula
compound
Prior art date
Application number
SI9520080A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9520080A (sl
Inventor
Beate Hellendahl
Annegret Lansky
Rainer Munschauer
Siegfried Bialojan
Liliane Unger
Hans-Juergen Teschendorf
Karsten Wicke
Karla Drescher
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of SI9520080A publication Critical patent/SI9520080A/sl
Publication of SI9520080B publication Critical patent/SI9520080B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
SI9520080A 1994-07-15 1995-07-14 Substituirane pirimidinske spojine in njihova uporaba SI9520080B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4425143A DE4425143A1 (de) 1994-07-15 1994-07-15 Substituierte Pyrimidinverbindungen und deren Verwendung
PCT/EP1995/002784 WO1996002519A1 (de) 1994-07-15 1995-07-14 Substituierte pyrimidinverbindungen und deren verwendung

Publications (2)

Publication Number Publication Date
SI9520080A SI9520080A (sl) 1998-04-30
SI9520080B true SI9520080B (sl) 2003-02-28

Family

ID=6523322

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9520080A SI9520080B (sl) 1994-07-15 1995-07-14 Substituirane pirimidinske spojine in njihova uporaba

Country Status (23)

Country Link
US (2) US6342604B1 (ko)
EP (1) EP0772603B1 (ko)
JP (1) JP3819024B2 (ko)
KR (1) KR100395394B1 (ko)
CN (1) CN1124269C (ko)
AT (1) ATE219063T1 (ko)
AU (1) AU703857B2 (ko)
BG (1) BG63257B1 (ko)
CA (1) CA2195241A1 (ko)
CZ (1) CZ295346B6 (ko)
DE (2) DE4425143A1 (ko)
DK (1) DK0772603T3 (ko)
ES (1) ES2178676T3 (ko)
FI (1) FI970150A0 (ko)
HU (1) HUT77535A (ko)
IL (1) IL114599A (ko)
NO (1) NO312030B1 (ko)
NZ (1) NZ290389A (ko)
PT (1) PT772603E (ko)
SI (1) SI9520080B (ko)
TW (1) TW455587B (ko)
WO (1) WO1996002519A1 (ko)
ZA (1) ZA955868B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
DE19735410A1 (de) * 1997-08-14 1999-02-18 Basf Ag 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
US6486162B2 (en) 1997-08-14 2002-11-26 Abbott Laboratories 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
SK4782001A3 (en) 1998-10-08 2001-11-06 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
AU2001250404A1 (en) * 2000-03-27 2001-10-08 Basf Aktiengesellschaft Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
CA2498936C (en) 2002-09-14 2013-02-12 Gov't Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Structurally rigid dopamine d3 receptor selective ligands and process for making them
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
DE10358004A1 (de) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
EP1694334B1 (en) 2003-12-18 2011-10-19 Abbott GmbH & Co. KG Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
EP1591455A1 (en) * 2004-04-29 2005-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Essential tremor diagnostic and treatment
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
DE102004027359A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
ATE452134T1 (de) 2004-08-09 2010-01-15 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
CN101039904B (zh) * 2004-10-14 2014-09-24 Abbvie德国有限责任两合公司 适于治疗对于多巴胺d3受体调节有反应的病症的杂环化合物
DE102004061593A1 (de) 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
US20060287485A1 (en) * 2005-06-17 2006-12-21 Crawford Emmett D Sound barriers comprising polyester compositions formed from 2,2,4,4-tetramethyl-1,3-cyclobutanediol and 1,4-cyclohexanedimethanol
WO2007113260A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
EP2007750B1 (en) * 2006-04-03 2013-08-21 Glaxo Group Limited Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors
PA8802101A1 (es) 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
CN105541702B (zh) * 2016-01-27 2019-10-22 宜春学院 类卢扎朵仑结构的芳胺基烷基硫类化合物及其制备方法
US11634404B2 (en) 2016-04-14 2023-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective D3 dopamine receptor agonists and methods of their use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1946472U (de) 1966-06-13 1966-09-22 Karl Schwarzwaelder Endstein der kotplate in stallboeden.
JPS4826777B1 (ko) 1969-08-18 1973-08-15
BE755015A (fr) * 1969-08-20 1971-02-01 Byk Gulden Lomberg Chem Fab Piperazinyl-alcoylamino-uraciles substitues par un groupe aryle, leurs ethers et thioethers, ainsi que leur procede de preparation
BE756127A (fr) 1969-09-12 1971-03-15 Hoechst Ag Ethers heterocycliques et leur preparation
GB1345449A (en) * 1971-05-14 1974-01-30 Science Union & Cie Pyridylpiperazines and process for their preparation
BE787126A (fr) * 1971-08-04 1973-02-05 Byk Gulden Lomberg Chem Fab Pyrimidines substituees, procedes de preparation de ces composes et medicaments contenant lesdits composes
BE787125A (fr) * 1971-08-04 1973-02-05 Byk Gulden Lomberg Chem Fab Pyrimidines substituees, leurs procedes de preparation et medicaments les contenant
BE792206A (ko) * 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
CA985683A (en) * 1972-10-27 1976-03-16 Gilbert Regnier Procede de preparation de n-amidoethyl piperazines
GR66581B (ko) * 1978-02-21 1981-03-27 Delalande Sa
FR2539990A1 (fr) * 1983-01-28 1984-08-03 Sanofi Sa Composition pharmaceutique a action psychotrope dopaminergique contenant une 2-piperazinopyrimidine
DE3609596A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
DE3609598A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
FR2631625B1 (fr) * 1988-05-17 1992-10-16 Synthelabo Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique
DE3840289A1 (de) * 1988-11-30 1990-05-31 Merck Patent Gmbh Aminosaeurederivate
JP2814600B2 (ja) * 1989-08-31 1998-10-22 正幸 石川 排尿障害治療剤
FR2663638B2 (fr) 1990-04-06 1995-02-10 Institut Nal Sante Recherc Medic Polypeptides ayant une activite de recepteur dopaminergique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides.
JP2518965B2 (ja) 1990-09-21 1996-07-31 三井東圧化学株式会社 新規ピリジン誘導体及びそれを有効成分として含有する制癌剤効果増強剤
FR2668771B1 (fr) 1990-11-06 1995-03-17 Inst Nat Sante Rech Med Acides nucleiques codant pour des polypeptides ayant une activite de recepteur dopaminergique humain et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides.
FR2678272B1 (fr) * 1991-06-27 1994-01-14 Synthelabo Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
ES2073951T3 (es) * 1992-07-03 1995-08-16 Synthelabo Derivados de 2-amino-n-(((4-(aminocarbonil)pirimidin-2-il)amino)alquil)pirimidina-4-carboxamida, su preparacion y su aplicacion en terapeutica.
FR2697253B1 (fr) * 1992-10-22 1994-12-02 Synthelabo Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique.
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
US5688795A (en) 1994-11-08 1997-11-18 Syntex (U.S.A.) Inc. 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists
HUT76266A (en) * 1995-10-31 1997-07-28 Egyt Gyogyszervegyeszeti Gyar New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components

Also Published As

Publication number Publication date
EP0772603A1 (de) 1997-05-14
DE4425143A1 (de) 1996-01-18
AU703857B2 (en) 1999-04-01
DK0772603T3 (da) 2002-07-15
SI9520080A (sl) 1998-04-30
NO312030B1 (no) 2002-03-04
IL114599A0 (en) 1995-11-27
CZ295346B6 (cs) 2005-07-13
DE59510244D1 (de) 2002-07-18
KR970704702A (ko) 1997-09-06
KR100395394B1 (ko) 2003-11-28
CN1124269C (zh) 2003-10-15
JP3819024B2 (ja) 2006-09-06
EP0772603B1 (de) 2002-06-12
FI970150A (fi) 1997-01-14
HU9700113D0 (en) 1997-02-28
US6342604B1 (en) 2002-01-29
CA2195241A1 (en) 1996-02-01
HUT77535A (hu) 1998-05-28
PT772603E (pt) 2002-11-29
ES2178676T3 (es) 2003-01-01
TW455587B (en) 2001-09-21
BG63257B1 (bg) 2001-07-31
CZ12397A3 (en) 1997-08-13
BG101110A (en) 1997-08-29
IL114599A (en) 1999-08-17
NO970162L (no) 1997-03-14
JPH10502659A (ja) 1998-03-10
US6444674B1 (en) 2002-09-03
FI970150A0 (fi) 1997-01-14
CN1152917A (zh) 1997-06-25
NZ290389A (en) 1999-03-29
ATE219063T1 (de) 2002-06-15
WO1996002519A1 (de) 1996-02-01
AU3111695A (en) 1996-02-16
NO970162D0 (no) 1997-01-14
ZA955868B (en) 1997-01-14

Similar Documents

Publication Publication Date Title
SI9520080B (sl) Substituirane pirimidinske spojine in njihova uporaba
SI9520084B (sl) Uporaba hetrocikličnih spojin kot dopamin-d3-ligandov
SI9520081B (sl) Uporaba tiazolnih in tiadiazolnih spojin
NZ336379A (en) Nitric oxide synthase inhibitor, use and process of preparation
AR034556A1 (es) Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado
HRP20120494T1 (hr) Derivati purina za uporabu kao agonista adenozin a2a receptora
YU56192A (sh) Heterociklični derivati
AR088808A2 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
DE122006000051I2 (de) Ester der 5-Aminolevulinsäure als Mittel zur Photosensibilisierung in der Chemotherapie
SE8204237L (sv) Karbostyrilforeningar, kompositioner innehallande dessa samt forfaranden for framstellning derav
CA2431952A1 (en) Muscarinic antagonists
NO306345B1 (no) Piperidin-derivater med PAF antagonist-aktivitet, anvendelse derav og farmasöytisk blanding
KR960704876A (ko) 혈소판 응집 저해 작용을 갖는 신규 화합물 (Novel Compound Having Platelet Aggregation Inhibitor Effect)
RU2012127709A (ru) Пирувамидные соединения в качестве ингибиторов аллергена пылевых клещей 1 группы, представляющего собой пептидазу, и их применение
RU92004509A (ru) Замещенные фенилфенольные соединения, фармацевтическая композиция, способ получения
DE69533194D1 (de) PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
FI943931A0 (fi) Indolijohdannaisia steroidi-5alfa-reduktaasin inhibiittoreina
IL71201A0 (en) Bactericidal compositions containing quinolonecarboxylic acid derivatives and certain such novel compounds
SI9520094B (sl) N-substituirani 3-azabiciklo/3.2.0/ heptanski derivati uporabni kot nevroleptiki
PE45195A1 (es) Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene
ES528462A0 (es) Procedimiento de preparacion de nuevos derivados dialquilaminoalcoxibencilalcoholicos y de sus sales de adicion acidas y amonicas cuaternarias
ATE80881T1 (de) Heteroarotinoid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DE69330601T2 (de) Serotoninergische ergolin derivate
KR950701329A (ko) 벤조티아졸술폰아미드 유도체, 그의 제조법 및 그 용도(Benzothiazolesulfornamide derivative, method for preparing the same, and use thereof)
ITMI910658A1 (it) N-(4, 5-diidrossi-e 4, 5, 8-triidrossi-9, 10-diidro-9, 10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20050412